Programme
Monday 10th May |
|
09:00 |
Welcome Address Sr Emilià Pola, IDIBELL, General Director Manel Esteller, MD, PhD. PEBC Director |
Session I: ANIMAL MODELS FOR TUMOR SUPPRESSORS Chair: David Sidransky |
|
09:15 |
Anton Berns Conditional tumor suppressor knockout mouse models for lung cancer and mesothelioma |
09:50 |
Suzanne Baker Tumor Suppressor Pathways in Gliomagenesis |
10:25 |
Short talk Jose Yelamos Functional interplay between Poly(ADP-ribose) polymerase-2 and p53 in tumour suppression |
10:40 |
Short talk Jesus Paramio Epithelial-mesenchymal transition and metastasis associated with deregulated miRNA expression in Trp53-deficient squamous cell carcinoma |
10:55 |
Coffee break and poster session |
11:30 |
Elisabeth P Henske Cancer mutations and targeted therapies in cells, mice and patients |
12:05 |
Manuel Serrano Tumor Suppressors beyond Cancer: role in Aging and Metabolism |
12:40 |
Short talk Maria L Martinez-Chantar Activation of LKB1-Akt pathway independent of PI3 Kinase plays a critical role in the development of hepatocellular carcinoma from NASH |
12:55 |
Lunch and poster session I |
Session II: FAMILIAL CANCER Chair: Elisabeth P. Henske |
|
14:30 |
Javier Benitez Familial breast cancer. Where are we and where do we go |
15:05 |
Conxi Lazaro Neurofibromatosis type 1: From mutation analysis to antisense therapeutics |
15:40 |
Eric Legius The Ras-o-pathies: inherited disorders of the RAS-pathway |
16:15 |
Coffee break and poster session |
16:45 |
Jordi Surralles Fanconi anemia: a paradigm of cancer prone syndrome |
17:20 |
Short talk Miquel Angel Pujana A molecular mechanism for mammary epithelial differentiation linked to BRCA1 and risk of breast cancer |
17:45 |
Short talk Laura Valle Blood telomere length and variation in telomere-related genes in hereditary and sporadic colorectal cancer patients |
Tuesday 11th May |
|
Session III: FAMILIAL CANCER: NOVEL THERAPIES AND CLINICAL MANAGEMENT Chair: Anton Berns |
|
9:30 |
Lauri Aaltonen Prevention of malignancy in hereditary nonpolyposis colorectal cancer; the Finnish experience |
10:05 |
Ian Tomlinson Tumour suppressor genes: still a useful concept? |
10:40 |
Short talk Hans-Guido Wendel EphA receptor signaling – a new, soluble tumor suppressor pathway in lymphoma |
10:55 |
Group Picture - Coffee break and poster session |
12:00 |
Alan Ashworth Synthetic Lethal Approaches to Cancer Therapy |
12:35 |
Short talk Jean Imbert The potential tumor suppressor GATA4 directly represses ERBB2 expression - Nuclear expression mechanism for the ERBB2 receptor and role in breast cancer cells |
12:50 |
Short talk Kucharczyk Krzysztof MSSCP genotyping method for a fast and cost effective detection of 1% of minor KRAS genetic variants in heterogenic clinical material |
13:05 |
Lunch and poster session |
Session IV: NOVEL TUMOR SUPPRESSORS Chair: Alan Ashworth |
|
14:30 |
David Sidransky Integrating molecular markers and tumorgrafts to personalize cancer therapy |
15:05 |
Alberto Bardelli Cancer mutations and targeted therapies in cells, mice and patients |
15:40 |
Short talk Pedro Lazo Double autoregulatory loop between VRK1-p53 and DRAM in response to genotoxic damage |
15:55 |
Coffee break and poster session |
16:30 |
Andre Futreal Somatic genetics of human cancer: moving towards large scale sequencing of cancer genomes |
17:05 |
Montse Sanchez-Cespedes Identification of novel tumor suppressor genes in lung cancer |
17:40 |
Short talk Hugo Prazeres Chromosomal, epigenetic and microRNA-mediated changes leading to LRP1B inactivation and modulation of the tumor microenvironment |
Closing remarks |
|
